1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Treatment variables of patients with acute ischemic stroke treated with IA thrombolysis
Variable Age <80 years (n = 81) Age ≥80 years (n = 33)
BP peak, intraprocedural, mm Hg, mean ± SD 
    Systolic 170 ± 21 180 ± 23
    Diastolic 92 ± 17 92 ± 16
Time from onset to start of IA infusion, min, mean ± SD 261 ± 150 257 ± 125
Time from onset to start of IA infusion 0–180 minutes, % 22% 12%
Time from onset to start of IA infusion 181–360 minutes, % 70% 67%
Time from onset to start of IA infusion >360 minutes, % 8% 21%
Time from onset to end of procedure, min, mean ± SD 334 ± 150 336 ± 128
Treatment regimen, n (%) 
    IA urokinase alone 33 (41%) 15 (45%)
    IA tPA alone 44 (54%) 15 (45%)
    IV/IA tPA 4 (5%) 3 (10%)
Total IA tPA dose, mg, mean ± SD^* 16.8 ± 10.5 17.2 ± 10.0
Note:—IA indicates intra-arterial; IV, intravenous; tPA, tissue plasminogen activator; BP, blood pressure.
* In patients receiving IA tPA